Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Covalent inhibitors have emerged as an important drug class in recent years, largely due to their many unique advantages as compared to noncovalent inhibitors, including longer duration of action, lower prolonged systemic exposure, higher potency, and selectivity. However, the potential off-target toxicity of covalent inhibitors, particularly of irreversible covalent inhibitors, represents a great challenge in covalent drug development. Therefore, accurate calculation of protein covalent inhibitor reaction kinetics to guide the design of selective inhibitors would greatly benefit covalent drug discovery efforts. In the present paper, we present a computational method to calculate the relative reaction kinetics between congeneric irreversible covalent inhibitors and their protein receptors. The method combines density functional theory calculations of the transition state barrier height of the rate-limiting step for reaction between the warhead of the inhibitor and a single protein residue, and molecular-mechanics-based free energy calculations to account for the interactions between the ligand in the transition state and the protein environment. The method was tested on four pharmaceutically interesting irreversible covalent binding systems involving 28 ligands; the mean unsigned error (MUE) of the relative reaction rate for all pairs of ligands between the predictions and experimental results for these tested systems is 0.79 log unit. This is to our knowledge the first time where the reaction kinetics of protein irreversible covalent inhibition have been directly calculated with physics-based free energy calculation methods and transition state theory. We anticipate the outstanding accuracy demonstrated here across a broad range of target classes will have a strong impact on the design of selective covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Possible toxicity arising from protein haptenization is also a potential risk of covalent PPI inhibitors [133, 134].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [134]
Citations
Cites
Grimme, S., Antony, J., Ehrlich, S., & Krieg, H. (2010) · The Journal of Chemical Physics · doi:10.1063/1.3382344 · Cited by 59,686
Stephens, P. J., Devlin, F. J., Chabalowski, C. F., & Frisch, M. J. (1994) · The Journal of Physical Chemistry · doi:10.1021/j100096a001 · Cited by 23,248
An improved algorithm for reaction path following
Gonzalez, C., & Schlegel, H. B. (1989) · The Journal of Chemical Physics · doi:10.1063/1.456010 · Cited by 6,159
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
Harder, E., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., et al. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5b00864 · Cited by 3,047
Self-citationEfficient estimation of free energy differences from Monte Carlo data
Bennett, C. H. (1976) · Journal of Computational Physics · doi:10.1016/0021-9991(76)90078-4 · Cited by 2,755
Combining Synchronous Transit and Quasi‐Newton Methods to Find Transition States
Peng, C., & Bernhard Schlegel, H. (1993) · Israel Journal of Chemistry · doi:10.1002/ijch.199300051 · Cited by 2,076
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Bochevarov, A. D., Harder, E., Hughes, T. F., Greenwood, J. R., Braden, D. A., Philipp, D. M., Rinaldo, D., Halls, M. D., Zhang, J., & Friesner, R. A. (2013) · International Journal of Quantum Chemistry · doi:10.1002/qua.24481 · Cited by 1,798
Self-citationWang, L., Wu, Y., Deng, Y., Kim, B., Pierce, L., Krilov, G., Lupyan, D., Robinson, S., Dahlgren, M. K., Greenwood, J., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512751q · Cited by 1,313
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Self-citationTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913
Self-citationJordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643
Self-citationA Universal Approach to Solvation Modeling
Cramer, C. J., & Truhlar, D. G. (2008) · Accounts of Chemical Research · doi:10.1021/ar800019z · Cited by 610
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439
Classical and modern methods in reaction rate theory
Berne, B. J., Borkovec, M., & Straub, J. E. (1988) · The Journal of Physical Chemistry · doi:10.1021/j100324a007 · Cited by 409
Structure-based design of targeted covalent inhibitors
Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344
Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069401 · Cited by 328
Advancing Drug Discovery through Enhanced Free Energy Calculations
Abel, R., Wang, L., Harder, E. D., Berne, B. J., & Friesner, R. A. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00083 · Cited by 327
Self-citationFlanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Self-citationCovalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Cannabinoids as Therapeutic Agents
(2019) · Chapman & Hall/CRC eBooks · doi:10.1201/9780429260667 · Cited by 311
Kinetic basis for selective inhibition of cyclo-oxygenases
Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K., & Isakson, P. C. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3390607 · Cited by 287
Boger, D. L., Sato, H., Lerner, A. E., Hedrick, M. P., Fecik, R. A., Miyauchi, H., Wilkie, G. D., Austin, B. J., Patricelli, M. P., & Cravatt, B. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5044 · Cited by 272
Hata, D., Kawakami, Y., Inagaki, N., Lantz, C. S., Kitamura, T., Khan, W. N., Maeda-Yamamoto, M., Miura, T., Han, W., Hartman, S. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1235 · Cited by 262
Chang, B. Y., Huang, M. M., Francesco, M., Chen, J., Sokolove, J., Magadala, P., Robinson, W. H., & Buggy, J. J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3400 · Cited by 231
Proudfoot, A. T., & Wright, N. (1970) · BMJ · doi:10.1136/bmj.3.5722.557 · Cited by 215
Wang, L., Deng, Y., Knight, J. L., Wu, Y., Kim, B., Sherman, W., Shelley, J. C., Lin, T., & Abel, R. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct300911a · Cited by 194
Self-citationLeproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 193
Ibrutinib: A First in Class Covalent Inhibitor of Bruton's Tyrosine Kinase
Davids, M. S., & Brown, J. R. (2014) · Future Oncology · doi:10.2217/fon.14.51 · Cited by 189
Automated Transition State Search and Its Application to Diverse Types of Organic Reactions
Jacobson, L. D., Bochevarov, A. D., Watson, M. A., Hughes, T. F., Rinaldo, D., Ehrlich, S., Steinbrecher, T. B., Vaitheeswaran, S., Philipp, D. M., Halls, M. D., et al. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00764 · Cited by 173
Self-citationPatel, V., Balakrishnan, K., Bibikova, E., Ayres, M., Keating, M. J., Wierda, W. G., & Gandhi, V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1446 · Cited by 145
Accurate Modeling of Scaffold Hopping Transformations in Drug Discovery
Wang, L., Deng, Y., Wu, Y., Kim, B., LeBard, D. N., Wandschneider, D., Beachy, M., Friesner, R. A., & Abel, R. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00991 · Cited by 136
Self-citationProspective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors
Kuhn, B., Tichý, M., Wang, L., Robinson, S. D., Martin, R. E., Kuglstatter, A., Benz, J., Giroud, M., Schirmeister, T., Abel, R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01881 · Cited by 133
Self-citationJongstra-Bilen, J., Puig Cano, A., Hasija, M., Xiao, H., Smith, C. I. E., & Cybulsky, M. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.288 · Cited by 132
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 107
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 82
Wang, Z., Watt, W., Brooks, N. A., Harris, M. S., Urban, J., Boatman, D., McMillan, M., Kahn, M. R., Heinrikson, R. L., Finzel, B. C., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.007 · Cited by 81
Range-Separated DFT Functionals are Necessary to Model Thio-Michael Additions
Smith, J. M. B., Jami‐Alahmadi, Y., & Rowley, C. N. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct400773k · Cited by 77
Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors?
Chatterjee, P., Botello‐Smith, W. M., Zhang, H., Qian, L., Alsamarah, A., Kent, D., Lacroix, J. J., Baudry, M., & Luo, Y. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08938 · Cited by 65
Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis
Kim, K., Maderna, A., Schnute, M. E., Hegen, M., Mohan, S., Miyashiro, J. S., Lin, L., Li, E., Keegan, S., Lussier, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.008 · Cited by 64
Barnes, T. A., O'Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00113 · Cited by 62
General Transition-State Force Field for Cytochrome P450 Hydroxylation
Rydberg, P., Olsen, L., Norrby, P., & Ryde, U. (2007) · Journal of Chemical Theory and Computation · doi:10.1021/ct700110f · Cited by 52
Liang, Q., Chen, Y., Yu, K., Chen, C., Zhang, S., Wang, A., Wang, W., Wu, H., Liu, X., Wang, B., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.001 · Cited by 23
Self-citationNew antiplatelet drugs: beyond aspirin and clopidogrel
Siddique, A., Butt, M. N., Shantsila, E., & Lip, G. Y. H. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02058.x · Cited by 22
Histamine release from human buffy coat-derived mast cells
Wang, X. S., & Lau, H. Y. A. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.11.005 · Cited by 9
Research works printed but not linked: 4
- American Chemical Society International Historic Chemical Landmarks. Discovery and Development of Penicillin. http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html (accessed Aug 30, 2015).
- Kuhn, 2017, Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors, J. Med. Chem., 60, 2485, 10.1021/acs.jmedchem.6b01881 · DOI
- 2019, Schrodinger Suite 2019 Protein Preparation Wizard
- Mechoulam, 1986, The Pharmacohistory of Cannabis sativa
Cited by
OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space
Lu, C., Wu, C., Ghoreishi, D., Chen, W., Wang, L., Damm, W., Ross, G. A., Dahlgren, M. K., Russell, E., Von Bargen, C. D., et al. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00302 · Cited by 2,005
Self-citationThe maximal and current accuracy of rigorous protein-ligand binding free energy calculations
Ross, G. A., Lu, C., Scarabelli, G., Albanese, S. K., Houang, E., Abel, R., Harder, E. D., & Wang, L. (2023) · Communications Chemistry · doi:10.1038/s42004-023-01019-9 · Cited by 178
Self-citationHahn, D., Bayly, C., Boby, M. L., Bruce Macdonald, H., Chodera, J., Gapsys, V., Mey, A., Mobley, D., Perez Benito, L., Schindler, C., et al. (2022) · Living Journal of Computational Molecular Science · doi:10.33011/livecoms.4.1.1497 · Cited by 84
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“Possible toxicity arising from protein haptenization is also a potential risk of covalent PPI inhibitors [133, 134].”
BackgroundRecent Advances in Alchemical Binding Free Energy Calculations for Drug Discovery
Muegge, I., & Hu, Y. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00541 · Cited by 88
Metadata
- Authors
- Yu, H. S., Gao, C., Lupyan, D., Wu, Y., Kimura, T., Wu, C., Jacobson, L., Harder, E., Abel, R., & Wang, L.
- Affiliations
- Schrodinger (United States) (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Wang, Lingle
- ORCID
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-08-19
- Volume
- 59
- Issue
- 9
- Pages
- 3955-3967
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2969628133
- Cited by
- 39
- References
- 53
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 9 · 2020: 6
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Chemical Information and Modeling (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Physics and Astronomy › Atomic and Molecular Physics, and Optics › Advanced Chemical Physics Studies
- Physical Sciences › Chemistry › Organic Chemistry › Physical Organic Chemistry and Reaction Kinetics
- Keywords
- irreversible covalent inhibitors, relative reaction rates, free energy calculation, molecular mechanics, density functional theory, off-target toxicity, atomistic modeling
- MeSH terms
- Enzyme Inhibitors, Kinetics, Models, Molecular, Protein Binding, Proteins, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.